According to Lianya Pharmaceutical's announcement, the total capital raised by the company's initial public offering of shares was 936 million yuan, and the net amount raised after deducting issuance fees was 868 million yuan, which has been examined by KPMG Huazhen Certified Public Accountants. In order to standardize the management and use of raised funds, the company set up special fund-raising accounts and signed “Tripartite Supervision Agreements” with China Construction Bank Nantong Economic and Technological Development Zone Branch, Agricultural Bank of China Nantong Branch, Bank of China Nantong Economic and Technological Development Zone Branch, and sponsor agency China International Finance Co., Ltd., respectively. The special account is only used for the storage and use of raised funds.

According to Lianya Pharmaceutical's announcement, the total capital raised by the company's initial public offering of shares was 936 million yuan, and the net amount raised after deducting issuance fees was 868 million yuan, which has been examined by KPMG Huazhen Certified Public Accountants. In order to standardize the management and use of raised funds, the company set up special fund-raising accounts and signed “Tripartite Supervision Agreements” with China Construction Bank Nantong Economic and Technological Development Zone Branch, Agricultural Bank of China Nantong Branch, Bank of China Nantong Economic and Technological Development Zone Branch, and sponsor agency China International Finance Co., Ltd., respectively. The special account is only used for the storage and use of raised funds.